Updates on new injectable plants is attached
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 4.1 pts more than Nifty Microcap 250 and 4.2 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Mercury Laboratories had earlier announced a new Small Volume Parenteral (SVP) injectable plant at Jarod (Baroda-Halol Road) with an annual capacity of 75 million units, estimated to cost INR 30 Crores. The plant, originally scheduled for commissioning in November 2025, has now been delayed by 13 months and is expected to be commissioned by December 2026. The delay is due to revised Schedule M guidelines from the Ministry of Health and Family Welfare, which require additional compliances and infrastructural upgrades for pharmaceutical manufacturing facilities. The company has stated there is no material adverse impact on overall business operations and is taking steps to expedite completion.
Short-term neutral to slightly negative — a 13-month delay in a INR 30 Crore capex project means revenue contribution from the new plant pushes to late 2026/early 2027, though management reassures no material business impact. Investors should track progress updates on the revised December 2026 timeline.